LeMaitre Vascular Inc (NASDAQ:LMAT) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 1,650,000 shares, a decrease of 6.3% from the September 30th total of 1,760,000 shares. Approximately 10.2% of the company’s stock are sold short. Based on an average daily trading volume, of 103,200 shares, the short-interest ratio is currently 16.0 days.

LeMaitre Vascular stock traded up $0.27 during midday trading on Tuesday, reaching $34.53. 1,383 shares of the company traded hands, compared to its average volume of 129,470. The firm has a market capitalization of $687.30 million, a price-to-earnings ratio of 41.10, a price-to-earnings-growth ratio of 3.88 and a beta of 1.21. The business has a 50 day moving average of $33.71 and a two-hundred day moving average of $30.82. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $37.35.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, October 23rd. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.04. LeMaitre Vascular had a net margin of 16.76% and a return on equity of 13.38%. The company had revenue of $29.10 million for the quarter, compared to the consensus estimate of $28.15 million. During the same quarter in the prior year, the firm earned $0.21 earnings per share. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. Sell-side analysts forecast that LeMaitre Vascular will post 0.89 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Wednesday, November 20th will be issued a dividend of $0.085 per share. The ex-dividend date is Tuesday, November 19th. This represents a $0.34 dividend on an annualized basis and a yield of 0.98%. LeMaitre Vascular’s dividend payout ratio is currently 40.48%.

In other news, CEO George W. Lemaitre sold 16,051 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $33.53, for a total value of $538,190.03. Following the transaction, the chief executive officer now owns 3,024,394 shares in the company, valued at $101,407,930.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David B. Roberts sold 12,202 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $35.29, for a total transaction of $430,608.58. Following the completion of the transaction, the director now owns 35,226 shares in the company, valued at approximately $1,243,125.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 104,410 shares of company stock worth $3,660,684. Insiders own 19.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Copeland Capital Management LLC increased its holdings in LeMaitre Vascular by 38.7% during the third quarter. Copeland Capital Management LLC now owns 536,199 shares of the medical instruments supplier’s stock valued at $18,327,000 after buying an additional 149,642 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in LeMaitre Vascular by 92.3% during the third quarter. Russell Investments Group Ltd. now owns 360,859 shares of the medical instruments supplier’s stock valued at $12,333,000 after buying an additional 173,214 shares during the last quarter. Comerica Bank increased its holdings in LeMaitre Vascular by 43.8% during the third quarter. Comerica Bank now owns 80,709 shares of the medical instruments supplier’s stock valued at $2,774,000 after buying an additional 24,592 shares during the last quarter. California Public Employees Retirement System increased its holdings in LeMaitre Vascular by 12.8% during the third quarter. California Public Employees Retirement System now owns 50,981 shares of the medical instruments supplier’s stock valued at $1,743,000 after buying an additional 5,783 shares during the last quarter. Finally, State of Tennessee Treasury Department increased its holdings in LeMaitre Vascular by 8.5% during the third quarter. State of Tennessee Treasury Department now owns 6,731 shares of the medical instruments supplier’s stock valued at $230,000 after buying an additional 529 shares during the last quarter. 79.72% of the stock is owned by institutional investors and hedge funds.

LMAT has been the topic of several analyst reports. BidaskClub downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 5th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $40.00 price objective on the stock in a research report on Saturday, October 26th. Lake Street Capital upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Thursday, October 24th. ValuEngine downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, October 7th. Finally, Barrington Research restated an “outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. LeMaitre Vascular currently has an average rating of “Buy” and an average target price of $39.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Further Reading: Monthly Dividend Stocks Can Provide Solid Income

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.